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Introduction
We have previously described a patient who developed dif-
fuse restenosis in the right coronary artery, where a bare 
metal stent (BMS) and two drug-eluting stents (DES) had 
been deployed sequentially 13 months before. We com-
pared the differences in pathological features between the 
restenosis lesion at the DES site and those at the BMS site, 
using specimens obtained by directional coronary atherec-
tomy (DCA). We observed delayed re-endothelialization 
and prolonged inflammation in the DES lesion relative to 
the BMS lesion [1]. Thereafter, we carefully followed this 
case for 5 years.
In the present report, we describe our latest findings at 
the stent sites in this case, in which we observed neointima 
formation over the stent strut by optical coherence tomog-
raphy (OCT) and coronary angioscopy (CAS).
Case report
A 70-year-old man with poorly controlled diabetes mel-
litus, who had a history of angina pectoris and coronary 
artery bypass surgery for three-vessel coronary artery 
disease, underwent percutaneous coronary intervention 
(PCI) for a native chronic total occlusion of the right coro-
nary artery (RCA), as the graft for the RCA had become 
obstructed. A BMS and two sirolimus-eluting stents (SES) 
were deployed at the proximal to distal portion, respec-
tively, with sequential edge to edge overlap to achieve full 
coverage of the longitudinal plaque (Fig. 1a). Thirteen 
Abstract A 70-year-old man underwent stent implanta-
tion for right coronary artery (RCA) lesions with a bare 
metal stent (BMS) and two sirolimus-eluting stents (SES). 
However, as both the BMS and SES stented sites devel-
oped restenosis after 13 months, he underwent target lesion 
revascularization using directional coronary atherectomy 
(DCA). On histopathology, the restenosis lesion at the 
SES-deployed site showed greater inflammation and less 
re-endothelialization than that at the BMS-deployed site. 
Three months later, the SES-deployed site developed a 
second restenosis, in which paclitaxel-eluting stents (PES) 
were implanted (PES-in-SES), while the BMS-deployed 
site was restenosis free. Five years later, restenosis was 
absent in these RCA lesions. However, by optical coher-
ence tomography and/or coronary angioscopy, the PES-
in-SES site in the RCA showed poor neointimal coverage 
over the stent struts and yellowish neointima, suggesting 
lipid-rich neoatheroma formation, whereas at the BMS 
site appropriate white neointima formation was observed. 
Drug-eluting stents still have problems of persistent inflam-
mation, inappropriate neointima formation, and neoath-
erosclerosis. Although we are now in the era of second 
generation DESs in which better stent performance would 
be promising, we should remember that we are obliged to 
continue to follow-up all patients in whom first generation 
DESs such as SES or PES have been placed.
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months later, in-stent restenosis had developed at both the 
BMS-deployed site and the SES-deployed site (Fig. 1b). 
DCA was performed for target lesion revascularization 
(TLR) under intravascular ultrasound guidance for both 
regions of post-BMS and post-SES. The site, where the 
BMS and SES were overlapping, was not treated by the 
DCA, because it was confirmed by the IVUS observation 
that the restenosis lesion was absent at the overlapping 
Fig. 1  a A bare metal stent 
(BMS) (yellow line) and two 
sirolimus-eluting stents (SES) 
(green lines) were deployed 
at the proximal and distal 
portions of the right coronary 
artery (RCA), respectively, with 
sequential edge to edge overlap 
to achieve full coverage of the 
longitudinal plaque. b Thirteen 
months later, in-stent restenosis 
had developed at both the BMS-
deployed site (white arrow) and 
the SES-deployed site (black 
arrows). c Three months after 
the target lesion revasculariza-
tion by balloon angioplasty 
following directional coronary 
atherectomy, a second resteno-
sis had developed at the SES 
site alone (black arrow). d A 
pair of paclitaxel-eluting stents 
(PES) were implanted in the 
second restenosis site (PES-in-
SES) (blue lines)
Fig. 2  Immunohistochemistry 
of tissue samples at restenosis 
lesions of the BMS-deployed 
site and the SES-deployed site, 
obtained by the directional 
coronary atherectomy (DCA) 
13 months after stent deploy-
ment. Dense accumulations 
of CD45+ lymphocytes and 
CD68+ macrophages were pre-
sent in the restenosis lesions at 
the SES site, but the accumula-
tion of inflammatory cells was 
slight in those at the BMS site. 
Endothelial cells as stained with 
von Willebrand factor (vWF) 
were present in the restenosis 
lesions at the BMS site, but 
absent from those at the SES 
site
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site. Immunohistochemistry of tissue samples obtained 
from the DCA showed dense accumulations of inflam-
matory cells such as T lymphocytes and macrophages 
in the restenosis lesions at the SES site, but not in those 
at the BMS site. It also revealed that, while endothelial 
cells were absent from the restenosis lesions at the SES 
site, they were present in those at the BMS site (Fig. 2) 
[1]. The TLR was successfully performed by balloon 
angioplasty following the DCA. However, 3 months later 
the patient complained of angina, and coronary angiog-
raphy showed a second restenosis at the SES site alone 
(Fig. 1c). Therefore, a pair of paclitaxel-eluting stents 
(PES) were implanted in the second restenosis site (PES-
in-SES) (Fig. 1d). Five years later, he was readmitted with 
unstable angina caused by a new lesion in the diagonal 
branch. Restenosis was not evident in the stented sites of 
the RCA lesions. When performing PCI for the diagonal 
branch lesion, we examined the neointima at the stent 
sites in the RCA by OCT and CAS. In the BMS-deployed 
site, the stent struts were well covered with homogeneous 
uniformly thick, white colored neointima (Fig. 3a). In the 
proximal PES-in-SES site, which was the most severe sec-
ond restenosis site post-SES stenting, a mild late catch-up 
phenomenon was observed angiographically, attenuated 
neointima was observed by the OCT, and the neointima 
was strongly yellowish on CAS (Fig. 3b). In the middle 
portion of the PES-in-SES site, stent struts were well cov-
ered by neointima, which was mildly yellowish on CAS 
(Fig. 3c, d). In the distal portion of the PES-in-SES site, 
the neointima was thin by OCT, and several stent struts 
were clearly visible by CAS (Fig. 3e).
During 5 years from the final PCI to the PES-in-
SES procedure, dyslipidemia was not strictly controlled 
(Fig. 4, upper panel) (HDL-cholesterol: 63.2 ± 8.2 mg/
dL; LDL-cholesterol: 101.9 ± 26.1 mg/dL; triglycer-
ides: 118.1 ± 34.5 mg/dL). Although serum uric acid was 
Fig. 3  The latest findings in the RCA lesions by coronary angiogra-
phy (upper panel), optical coherence tomography (OCT) and coro-
nary angioscopy (CAS) (lower panel). In the BMS-deployed site, 
stent struts were well covered with homogeneous uniformly thick, 
white colored neointima (a). In the proximal PES-in-SES site, a mild 
late catch-up phenomenon was observed angiographically, attenuated 
neointima was observed by OCT, and the neointima was strongly yel-
lowish on CAS (b). In the middle portion of the PES-in-SES site, the 
stent struts were well covered by neointima, which was mildly yel-
lowish on CAS (c, d). In the distal portion of the PES-in-SES site, 
neointima was thin on OCT, and several stent struts were clearly vis-
ible by CAS (e)
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maintained at low levels (3.7 ± 0.7 mg/dL), diabetes was 
poorly controlled (hemoglobin A1c: 9.3 ± 1.6 %), and the 
serum creatinine concentration gradually increased (Fig. 4, 
lower panel).
Discussion
The patient underwent repeated revascularization. Since 
the graft for the RCA became occluded, a BMS and two 
SESs were sequentially implanted in the native RCA. How-
ever, 13 months later restenosis had developed in both the 
BMS-deployed and SES-deployed sites. We selected DCA 
for TLR at both sites, because this patient had poorly con-
trolled diabetes, and thus, less injury by applying DCA 
technology would have been promising. Surprisingly, the 
histopathological features of the restenosis lesions, sam-
ples of which were taken using DCA, were quite different. 
The SES-restenosis lesions showed less endothelial regen-
eration and a greater inflammatory reaction than the BMS-
restenosis lesions, as mentioned in our previous case report 
[1]. We have also observed similar histopathological find-
ings in several other cases [2].
After the first revascularization, restenosis did not occur 
at the BMS-restenosis site during long-term follow-up of 
more than 5 years. In the SES-restenosis site, on the other 
hand, restenosis recurred after 3 months. Finally, this site 
was treated with the PES-in-SES technique, after which these 
RCA lesions remained free of restenosis for 5 years, although 
a new lesion in the diagonal branch developed. In the present 
report, the most important finding is that by OCT and/or CAS 
the restenosis-free PES-in-SES site in the RCA showed poor 
neointimal coverage over the stent struts and yellowish neoin-
tima, suggesting in-stent lipid-rich neoatheroma formation. 
Previously neointimal tissue characterization was compared 
between DESs and BMS using iMap intravascular ultrasound 
(IVUS) observation. As a result, DES implantation was asso-
ciated with more-necrotic and less-fibrotic neointimal forma-
tion, suggesting the development of in-stent neoatherosclero-
sis [3]. This finding would be in substantial agreement with 
our present data. Although the IVUS-based tissue characteri-
zation might be useful to assess the in-stent neoatheroma, we 
Fig. 4  Course of risk factor parameters during 5 years from the 
final percutaneous coronary intervention. Dyslipidemia was well 
controlled (upper panel). Although serum uric acid was maintained 
at low concentrations, diabetes was not treated optimally, and serum 
creatinine progressively increased (lower panel)
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believe that OCT and/or CAS observation in our study would 
have greater advantage to assess neointimal coverage.
Drugs coated on the surface of drug-eluting stents (DES) 
are potent anti-mitotic and anti-inflammatory agents that 
strongly inhibit smooth muscle cell proliferation and matrix 
growth, thereby reducing neointima formation and reste-
nosis [4–6]. Although DES has substantially reduced the 
problem of restenosis, a separate issue has arisen distinct 
from restenosis, namely the potential for impairment of re-
endothelialization, which can lead to insufficient neointimal 
coverage and subsequent stent thrombosis, the latter some-
times occurring very late after implantation [7–9]. Impaired 
re-endothelialization may also delay wound healing and 
cause a relapse of inflammation when the anti-inflamma-
tory effects of the drugs on the DES have disappeared [10], 
leading to neoatherosclerosis with vulnerable plaque (i.e., 
neoatheroma formation) at the stented sites [11–13]. There-
fore, the overall performance of a stent should be character-
ized by the geometric luminal gain acquisition, appropriate 
neointima formation to achieve sufficient stent strut cover-
age, and prevention of neoatherosclerosis.
The most important message from this case report is that 
both the restenosis lesion 13 months after the first PCI and 
the restenosis-free site 5 years after the final PCI showed 
strong inflammatory features and less re-endothelialization 
after DES placement, whereas the BMS placement site did 
not do so. Since diabetes and dyslipidemia were not treated 
optimally and renal function progressively deteriorated in 
this case, it cannot be denied that these factors contributed 
to the lesion outcomes.
This case demonstrates that although DES can achieve 
satisfactory geometric luminal gain, the problems of persis-
tent inflammation, inappropriate neointima formation and 
neoatherosclerosis remain to be overcome. Finally, the SES 
and PES used in this case are first generation DESs, nei-
ther of which is now available. Although we are now in the 
era of second generation DESs in which better stent per-
formance would be promising [14], we should remember 
that we are obliged to continue to follow-up all patients in 
whom first generation DESs have been placed.
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